Please find enclosed Annual Report for the FY 2025-26.

Ref: ISLL:CH:2026 Date: 5th September, 2026 The President The Vice President, Corporate Relationship Department Listing Compliance Department, BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor 25th Floor, Dalal Street, Plot No. C/2, G-Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (E), Mumbai 400 051 BSE Scrip Code: 532305 NSE Symbol: INDSWFTLAB SUBJECT: - SUBMISSION OF ANNUAL REPORT FOR THE FINANCIAL YEAR 2025-26 This is to inform you that the 31st Annual General Meeting (“AGM”) of Ind-Swift Laboratories Limited will be held through Video Conferencing/Other Audio Visual Means (“VC/OAVM”) on Wednesday, 30th September, 2026, at 3:00 P.M. to transact the Business, as set out in the Notice of the Annual General Meeting in compliance with the applicable provisions of the Companies Act, 2013 and Rules made thereunder read with relevant Circulars issued by the Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI). In accordance with Section 108 of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014, the Company has fixed Wednesday, 23rd September, 2026, as the Cut-Off Date to determine the entitlement of the members to cast their votes for the businesses to be transacted at the ensuing AGM of the Company. Other important information including a detailed procedure for remote e-voting before and during the AGM is provided in the notes to the AGM Notice. Pursuant to Section 91 of the Companies Act, 2013 and the Rules framed thereunder and Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and Share Transfer Books of the Company will remain closed from Thursday, 24th September, 2026 to Wednesday, 30th September, 2026 (both days inclusive) for the purpose of the 31st AGM. The Annual Report of the Company for the Financial Year 2025-26 along with the Notice convening the 31st Annual General Meeting of the Company is enclosed herewith. You are requested to kindly take the same on record. Thanking You For IND-SWIFT LABORATORIES LTD. PARDEEP VERMA VP-CORPORATE AFFAIRS & COMPANY SECRETARY National Securities Depository Limited Central Depository Services (India) Limited Trade World, 4th Floor, Kamala Mills Marathon Futurex, A – Wing, 25th Floor, N. M. Compound, Senapati Bapat Marg, Lower Joshi Marg, Lower Parel – East, Mumbai – Parel, Mumbai – 400013 400013 Annual 2025 Report Next Chapter Ind-Swift Laboratories Ltd From Transformation to Value Creation. Ind-Swift Laboratories is a focused, global partnerships. Its manufacturing pure-play finished dosage formulations facilities hold approvals from the UK company. A single listed entity with zero MHRA, TGA, Health Canada and WHO Contents external debt and the capacity to fund GMP. Its R&D centre in Panchkula has every phase of its growth from internal more than 45 active programmes in the accruals. pipeline. Its commercial reach spans 85+ countries, with own-brand operations CORPORATE OVERVIEW The Company's strengths sit at the across the UAE, Central Asia, Africa and The Next Chapter 01 intersection of formulation science, South East Asia. Chairman’s Statement 16 regulatory precision and long-standing Statement by The Managing Director, Global Operations 20 Statement by The Managing Director, Domestic Operations 22 Ind-Swift Laboratories About the Company 24 A Journey of Growth and Evolution 26 today is leaner, clearer and Our Esteemed Clientele 28 Our Global Footprint 30 built for a different kind of Our Operating Environment 32 Our Manufacturing Capabilities 36 growth. Regulatory Approvals and Compliance 40 Research and Development 42 Corporate Social Responsibility and People Development 46 HR Initiatives – Caring for Our People 48 TRANSFORM. STATUTORY REPORTS INNOVATE. Management Discussion and Analysis 50 Corporate Information 66 COMMERCIALISE. Director's Report 67 SCALE. Report on Corporate Governance 94 STRENGTHEN. FINANCIAL STATEMENTS Standalone Financial Statements 124 GROW. Consolidated Financial Statements 187 NOTICE Notice of AGM 250 Six words. One connected journey. And a company whose best years now sit ahead of it. Corporate Overview Statutory Reports Financial Statements 01 Transform A Company Rebuilt from First Principles For nearly three decades, Ind-Swift operated across the pharmaceutical value chain, from active ingredients to finished dosages, across multiple entities. It was a broad business, but that breadth came at a cost: operational complexity, pressure on the balance sheet and a corporate structure that diluted focus. The Reset was Decisive. In 2024, Ind-Swift divested its API and CRAMS business to Synthimed Labs, backed by Bain Capital and Piramal through the India Resurgence Fund, in a I1,650 Crores transaction. Simultaneously, Ind-Swift Limited merged into Ind-Swift Laboratories Limited through an NCLT-approved consolidation, creating a single listed entity. The Result A unified, formulation-led company with a zero debt balance sheet and the freedom to invest from its own accruals. This was more than a financial restructuring. It was a re- architecture of the business around a clear thesis: that Ind-Swift's deepest competitive advantages lie in formulation science, regulatory expertise and long-standing global partnerships. Everything that followed in FY26 and everything that will follow in the years ahead, flows from this single, The reset rebuilt the foundational decision. core. What comes next reveals its full potential. 02 ANNUAL REPORT 2025-26 IND-SWIFT LABORATORIES LTD. 03 Corporate Overview Statutory Reports Financial Statements 02 Innovate Where Formulation Science Meets Commercial Ambition Ind-Swift's R&D centre in Panchkula, recognised by the Department of Science and Technology since 1995, is where the Company's future pipeline takes shape. During FY26, the team grew from 50 to over 70 scientists, the pipeline expanded from 30 to more than 45 active programmes and 15 new products added all targeting Europe, Australia, Canada and Brazil. The direction of this work matters as much as its scale. Ind-Swift is moving beyond conventional oral solid dosages into complex formulation platforms: gastro- resistant pellet systems (MUPS), delayed-release technologies and prolonged- release tablets. During the year, the team developed Mirabegron Prolonged Release Tablets (25 mg and 50 mg), a technically demanding formulation that required precision in release-rate engineering. It also advanced Mesalazine GR MUPS in both sachet and tablet formats and completed Esomeprazole GR MUPS capsules and tablets. Six bioequivalence studies went directly to the pivotal stage, bypassing pilot studies entirely. That is a measure of how much confidence the team has built in its formulation design over the past two years. We are well equipped to develop ointments, creams and gels, with new products targeted for development over the next 2–3 years. This expansion strengthens our product development platform and opens a second axis of growth. Innovation is where future revenue begins. A deeper pipeline creates From Ideas Today to Revenue Tomorrow more pathways to filing, 45+ 15+ 70+ 6 approval and market entry. Products in New Products Scientists Process Innovation Development. Added in FY26. Powering R&D. Patents Filed. 04 ANNUAL REPORT 2025-26 IND-SWIFT LABORATORIES LTD. 05 Corporate Overview Statutory Reports Financial Statements 03 Commercialise Science Reaches the Patient When It Reaches the Market A strong pipeline has value only when it converts into regulatory approvals, commercial partnerships and products on pharmacy shelves. During FY26, Ind-Swift accelerated that conversion. Throughout the year, the Company shared 285 dossiers with partners and regulatory authorities worldwide and received 69 new approvals across Europe, the UK, Canada, Saudi Arabia and several emerging markets. On th [Showing first 8,000 characters — download PDF for full document]